{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005317","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2026-08-06T20:02:32+00:00","discovered_at":"2026-08-06T20:04:01.419413+00:00","generated_at":"2026-08-06T20:04:28.467643+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corvus reports Q2 2026 net loss of $18.0M; cash $215.2M, runway into 2Q28","bullets":["Net loss $18.0M in Q2 2026 vs $8.0M in Q2 2025; R&D expenses $16.0M vs $7.9M.","Cash, equivalents and marketable securities $215.2M at June 30, 2026 (incl. $189.4M from Jan 2026 financing) vs $56.8M at Dec 2025; runway into 2Q28.","Soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis enrollment on track; plans to start hidradenitis suppurativa and asthma trials later 2026.","Invested $5.0M in Angel Pharma equity financing for soquelitinib trials in China.","Angel Pharma to initiate Phase 2 asthma trial early 2027; Corvus to start Phase 1b hidradenitis suppurativa and Phase 2 asthma trials later 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005317","json":"https://secwatch.observer/filing/0001171843-26-005317.json","markdown":"https://secwatch.observer/filing/0001171843-26-005317.md","text":"https://secwatch.observer/filing/0001171843-26-005317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/0001171843-26-005317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/f8k_080626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:04:28.467643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}